Adalimumab more effective as first-line anti-TNF-a therapy for uveitis

Adalimumab had better efficacy when used as the first anti-tumor necrosis factor-alpha treatment for childhood chronic uveitis than when used after infliximab failed, according to study results.In an open-label, multicenter study, Italian researchers evaluated 26 patients (median age, 8.6 years; 14 female) with resistant, noninfectious active uveitis. The children were enrolled in two treatment groups, due to the refractory course of uveitis to previous disease-modifying antirheumatic drugs. Fourteen children (group 1; 10 with juvenile idiopathic arthritis (JIA), three with idiopathic uveitis and one with Behçet’s syndrome) received adalimumab (24 mg/m2, (Read more...)

Full Story →